18:10 , Apr 23, 2019 |  BioCentury  |  Finance

Accelerating innovations in Cambridge

As the Cambridge, U.K., life sciences start-up environment continues to flourish, Cambridge Innovation Capital’s Michael Anstey believes the city lacked a crucial element to foster start-ups’ growth: a “true U.S.-style accelerator” to provide capital, mentorship...
23:41 , Apr 19, 2019 |  BioCentury  |  Product Development

Companies poised to take Chinese checkpoints global

At least three companies are well positioned to answer FDA Oncology chief Richard Pazdur’s call to bring Chinese PD-1/PD-L1 inhibitors to the U.S. to compete on price. Two Chinese drugmakers and one U.S. company globally...
17:46 , Feb 8, 2019 |  BC Week In Review  |  Financial News

DNAnexus raises $68M to advance its bioinformatics platform

DNAnexus Inc. (Mountain View, Calif.) raised $68 million in a financing that will enable the bioinformatics company to advance its DNAnexus Apollo platform. DNAnexus launched the cloud-based platform in October. It provides users access to...
18:32 , Feb 6, 2019 |  BC Extra  |  Financial News

DNAnexus raises $68M to advance its bioinformatics platform

DNAnexus Inc. (Mountain View, Calif.) raised $68 million in a financing that will enable the bioinformatics company to advance its DNAnexus Apollo platform. DNAnexus launched the cloud-based platform in October. It provides users access to...
04:43 , Dec 15, 2018 |  BioCentury  |  Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
01:59 , Aug 18, 2018 |  BioCentury  |  Product Development

Agreement to differ

FDA’s approval of Alnylam’s Onpattro marks the start of a showdown in the Orphan disease hATTR amyloidosis, with Akcea’s Tegsedi likely coming to the U.S. market in less than two months. Alnylam has used its...
20:09 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Gaucher disease Mouse studies suggest a GBA-based gene therapy could help treat Gaucher disease, which is caused by GBA mutations. In mouse dams pregnant with Gaucher disease fetuses, fetal administration via intracranial injection of...
22:04 , Jul 19, 2018 |  BC Innovations  |  Tools & Techniques

Immunotherapy Matchmaking

MD Anderson Cancer Center is using its access to patient samples to inject more rationality into decisions about which therapies should be paired with checkpoint inhibitors, and how to optimize the combos. The goal is...
13:01 , Jul 17, 2018 |  BC Extra  |  Preclinical News

Fetal gene therapy could treat neurodegenerative disease

A gene therapy virally delivered in utero or postnatally could help treat an acute form of Gaucher's disease, according to a Nature Medicine paper from University College London researchers and colleagues. Mutations in glucocerebrosidase (GBA;...
14:58 , Jun 8, 2018 |  BioCentury  |  Finance

Nimbus looks inward

Nimbus plans to use a $65 million financing it raised on Tuesday to take programs deeper in development, refining its founding strategy of partnering its compounds early on. Existing investor Atlas Venture led the round,...